Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK mRNA-based multivalent seasonal influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK mRNA-based multivalent seasonal influenza vaccine (GSK4393103A) is an investigational mRNA vaccine candidate developed by GSK for the prevention of seasonal influenza. The vaccine utilizes a messenger RNA platform to encode for hemagglutinin (HA) antigens from multiple influenza A and B strains. By delivering these genetic instructions, the vaccine prompts the recipient's cells to produce the viral proteins, thereby stimulating a robust immune response, including the production of neutralizing antibodies and T-cell activation. This mRNA approach is designed to offer improved manufacturing speed and potentially higher efficacy compared to traditional egg-based vaccines, particularly in matching circulating strains. Following the termination of its collaboration with CureVac for this program in 2024, GSK assumed full control of the development. It is currently in Phase 2 clinical evaluation.
- Other names
- mRNA-based multivalent seasonal influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GSK mRNA-based multivalent seasonal influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK mRNA-based multivalent seasonal influenza vaccine.